Back to top
more

Bausch Health (BHC)

(Delayed Data from NYSE)

$8.18 USD

8.18
4,700,118

+0.16 (2.00%)

Updated Sep 19, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (33 out of 251)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bausch Gains 38.9% YTD on Product Launches & Debt Reduction

by Zacks Equity Research

Bausch (BHC) is currently focusing on widening its ophthalmology and dermatology portfolio.

Indrajit Bandyopadhyay headshot

Price Stabilization Leads to Generic Drugs Industry's Recovery

by Indrajit Bandyopadhyay

Stabilizing prices of generic drugs is leading to a recovery in revenues of industry participants. New launches are also providing a boost. However, competition remains stiff.

Dova Receives Approval for Doptelet in Europe, Stock Up

by Zacks Equity Research

Dova Pharmaceuticals (DOVA) announces approval of its thrombocytopenia drug, Doptelet, in Europe for patients with chronic liver disease.

Is Bausch Health (BHC) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Bausch Health (BHC) Catches Eye: Stock Jumps 6.2%

by Zacks Equity Research

Bausch Health (BHC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Allergan Up As Analyst Statement Sparks Business Split Rumors

by Zacks Equity Research

Allergan's (AGN) shares up following a conference call with one of the company's executives, which led an analyst to believe that a split of the company's business is in the cards.

Is Bausch Health (BHC) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Why Is Bausch (BHC) Down 16.2% Since Last Earnings Report?

by Zacks Equity Research

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Bausch Health Cos (BHC) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (BHC) Outperforming Other Medical Stocks This Year?

Is Bausch Health (BHC) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

All You Need to Know About Bausch (BHC) Rating Upgrade to Buy

by Zacks Equity Research

Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Aerie (AERI) Q1 Earnings Beat, Rhopressa Misses Estimates

by Zacks Equity Research

Aerie (AERI) reports narrower-than-expected Q1 loss. However, Rhopressa lags expectations.

Options Traders Expect Huge Moves in Bausch Health (BHC) Stock

by Zacks Equity Research

Investors need to pay close attention to Bausch Health (BHC) stock based on the movements in the options market lately.

Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Bausch (BHC) Q1 earnings surpass estimates, while revenues miss the same. The increase in guidance was impressive.

Bausch Health (BHC) Q1 Earnings Top Estimates

by Zacks Equity Research

Bausch (BHC) delivered earnings and revenue surprises of 15.73% and -1.19%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for Bausch Health (BHC) Q1 Earnings?

by Zacks Equity Research

Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q1 results on May 6.

Bausch Health (BHC) Reports Next Week: What Awaits?

by Zacks Equity Research

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Bausch Health (BHC) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs

by Zacks Equity Research

Dr. Reddy's (RDY) inks agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.

Is Bausch Health (BHC) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

All You Need to Know About Bausch (BHC) Rating Upgrade to Buy

by Zacks Equity Research

Bausch (BHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aerie (AERI) Improves 22% YTD: Is Momentum Likely to Sustain?

by Zacks Equity Research

Aerie (AERI) gains momentum on the back of the FDA approval of its second drug, Rocklatan.

    Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge

    by Zacks Equity Research

    Aldeyra (ALDX) announced positive top-line data from a phase III study on pipeline product, reproxalap topical ophthalmic solution in patients with allergic conjunctivitis.

    Why Is Bausch (BHC) Up 8.3% Since Last Earnings Report?

    by Zacks Equity Research

    Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Is Bausch Health Companies (BHC) a Great Stock for Value Investors?

    by Zacks Equity Research

    Is Bausch Health Companies (BHC) a great pick from the value investor's perspective right now? Read on to know more.